Inhibrx Biosciences INBX
NASDAQ INBX
$99.46 -0.62 (-0.62%)
As of: Oct 1, 2026 · 12:00 PM EDT

Inhibrx Biosciences (INBX) Net Income (2023 - 2026)

Updated

Inhibrx Biosciences (INBX) recorded Net Income of -$36.65 million in Q2 2026, compared with -$28.65 million a year earlier.

Analysis

Inhibrx Biosciences (INBX) Net Income (2023 - 2026) Analysis & Trends

On a TTM basis, Inhibrx Biosciences' Net Income came in at -$133.39 million as of Jun 30, 2026; for FY2025, it came in at -$140.06 million.

  • Across earlier years, Net Income came in at $1.69 billion in FY2024 and -$239.73 million in FY2023.
  • The Q2 2026 figure is the lowest quarterly Net Income since Q1 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 5.53 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 3.62 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -1.34 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 3.26 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 2.51 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 2.38 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -10.50 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -237.00 Mn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 1.10 Bn
10 Inhibrx Biosciences 1.47 Bn 1.47 Bn - -36.65 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -36.65 Mn
Dec 31, 2025 -32.83 Mn
Sep 30, 2025 -35.26 Mn
Jun 30, 2025 -28.65 Mn
Mar 31, 2025 -43.31 Mn
Dec 31, 2024 -47.87 Mn
Sep 30, 2024 -43.86 Mn
Jun 30, 2024 1.86 Bn
Mar 31, 2024 -78.71 Mn
Dec 31, 2023 -91.97 Mn
Sep 30, 2023 -51.79 Mn
Jun 30, 2023 -47.05 Mn
API Access

Inhibrx Biosciences Net Income API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-income&ticker=INBX&period=max&api_key=YOUR_API_KEY